Tara B. Sanft, MD, on How Diet and Exercise May Affect Completion of Chemotherapy for Breast Cancer
2022 ASCO Annual Meeting
Tara B. Sanft, MD, of Yale University, discusses the results of the LEANer study (Lifestyle, Exercise, and Nutrition Early After Diagnosis) in women with breast cancer. It showed that patients with newly diagnosed disease who were just starting chemotherapy could improve physical activity and diet quality. While both groups had high rates of treatment completion, women in the intervention who exercised at or above the recommended levels did better in terms of treatment completion, with fewer dose reductions and delays (Abstract 12007).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We know completing chemotherapy as prescribed is important for cancer outcomes. We also know that adopting healthy diet and exercise is important, both for cancer prevention and, in certain cancers, can improve cancer-related survival. The healthy diet and exercise guidelines include eating a predominantly plant-based diet and exercising with moderate intensity exercise at least 150 minutes per week, and performing two strength training sessions per week. Our study, the Lifestyle, Exercise, and Nutrition Study, randomized women who were not meeting these guidelines to a healthy diet and exercise intervention based on the Diabetes Prevention Protocol and adapted using the cancer-related guidelines as well versus usual care, which is referral to our survivorship clinic and dieticians and exercise programs at request by the patient. Our primary outcome was looking at the relative dose intensity, or the actual amount of chemotherapy received compared to that which was prescribed. The intervention group received a year-long intervention of 16 sessions administered by a registered dietician who was certified, specialized in oncology, and also had exercise counseling training. The control group were followed at baseline post-chemotherapy. What we found was that both groups completed chemotherapy at very high rates, with both groups approaching about 93% completion rates. This is higher than what we had found in the literature before. We also found that the number of dose delays and reductions were similar between the two groups. When we looked at the intervention group, in particular, and we looked at if they were meeting the actual recommendations, that is 150 minutes per week and a high consumption of fruits and vegetables, we found that women who were able to meet these guidelines or exceeded them, did have higher completion rates compared to those who didn't quite make those guidelines. So in summary, the women who made the highest number of changes or adhered the best did have better relative dose intensity and fewer dose reductions and delays. But when we took the entire intervention group and compared them to usual care, we did not find a statistically significant difference. In summary, both groups completed their chemotherapy as prescribed most of the time, and the intervention group significantly improved both their diet and physical activity during the course of the intervention. Those who were able to adopt the exercise and diet recommendations the best did have significant improvements in their completion rates and fewer dose reductions and delays compared to those who didn't adopt it as well.
Related Videos
The ASCO Post Staff
Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute, and Ian E. Krop, MD, PhD, of Yale Cancer Center, discuss phase I/II findings on patritumab deruxtecan, a HER3-directed antibody-drug conjugate, in patients with HER3-expressing metastatic breast cancer. A pooled analysis showed antitumor activity in women with HR-positive/HER2-negative and HER2-positive advanced disease, as well as triple-negative breast cancer (Abstract 1002).
The ASCO Post Staff
Timothy J. Whelan, MD, of McMaster University and Hamilton Health Sciences, discusses findings from the LUMINA study, which found that women aged 55 or older who had grade 1–2 T1N0 luminal A breast cancer following breast-conserving surgery and were treated with endocrine therapy alone had very low rates of local tumor recurrence at 5 years. These patients, the research suggests, may be able to forgo radiotherapy (Abstract LBA501).
The ASCO Post Staff
Alfredo Carrato, MD, PhD, of Alcala de Henares University in Spain, discusses phase II results from the SEQUENCE trial, which showed that nab-paclitaxel, gemcitabine, and modified FOLFOX showed significantly higher clinical activity than the standard nab-paclitaxel and gemcitabine in the first-line setting of patients with untreated metastatic pancreatic ductal adenocarcinoma (Abstract 4022).
The ASCO Post Staff
Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement). They show that, even though Black patients comprise between 4% and 6% of all clinical trial participants, Black women with metastatic breast cancer are willing to consider taking part if steps were taken to increase their awareness, build trust through clear communication with health-care providers, involve people of shared racial/ethnic identity and health experience, and help patients find and access trials (Abstract 1014).
The ASCO Post Staff
Clifford A. Hudis, MD, of the American Society of Clinical Oncology, and Karen E. Knudsen, PhD, MBA, of the American Cancer Society, discuss their collaboration, pooling their research and education resources to help empower patients with cancer and their families. Within 48 hours, Drs. Hudis and Knudsen were able to gear up a rapid response to the crisis in Ukraine, forming a clinical corps of volunteers to post information online in multiple languages, which helped patients navigate their care in the war-torn region. To date, 300 European cancer organizations have joined their efforts.